These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 2034876)

  • 1. [Medical therapy of portal hypertension due to liver cirrhosis].
    Cerini R; Sperandeo M; Varriale A; De Rosa ML; Cacciatore L
    Recenti Prog Med; 1991 Feb; 82(2):91-9. PubMed ID: 2034876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Physiopathologic basis of medical therapy of portal hypertension in cirrhosis].
    Gatta A; Bolognesi M; Sacerdoti D; Merkel C
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():39S-47S. PubMed ID: 9004819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New trends in the treatment of hemodynamic disorders in liver cirrhosis].
    Vorob'ev LP; Maev IV
    Klin Med (Mosk); 1991 Sep; 69(9):11-4. PubMed ID: 1687073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamics in the isolated cirrhotic liver.
    Zipprich A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of portal hypertension.
    González-Abraldes J; Bosch J; García-Pagán JC
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1407-13. PubMed ID: 11890356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of lisinopril and nebivolol therapy of portal hypertension and kidney dysfunction in patients with liver cirrhosis].
    Fedulenkova LV; Drozdov VN; Mikheeva OM; Petrakov AV
    Eksp Klin Gastroenterol; 2008; (5):37-41. PubMed ID: 19145915
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
    Testro AG; Angus PW
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
    [No Abstract]   [Full Text] [Related]  

  • 8. Pulmonary complications in cirrhosis.
    Sussman NL; Kochar R; Fallon MB
    Curr Opin Organ Transplant; 2011 Jun; 16(3):281-8. PubMed ID: 21543981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blockers and portal hypertension, hemodynamic effects and prevention of recurrent gastrointestinal bleeding.
    Lebrec D
    Hepatogastroenterology; 1990 Dec; 37(6):556-60. PubMed ID: 1981204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pharmacological agents on portal hypertension: a haemodynamic appraisal.
    Bosch J
    Clin Gastroenterol; 1985 Jan; 14(1):169-84. PubMed ID: 2859134
    [No Abstract]   [Full Text] [Related]  

  • 12. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.
    Garbuzenko DV
    World J Gastroenterol; 2015 May; 21(20):6117-26. PubMed ID: 26034348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic treatment of portal hypertension.
    Rodríguez-Pérez F; Groszmann RJ
    Gastroenterol Clin North Am; 1992 Mar; 21(1):15-40. PubMed ID: 1349005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological control of portal hypertension.
    Polio J; Groszmann RJ
    Prog Liver Dis; 1993; 11():231-49. PubMed ID: 8272513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of portal hypertension with nadolol in patients with liver cirrhosis.
    Cervera J; Torres-Zamora M; Gutiérrez-Carreño R; Fierro M; Schaeffer L; Landa L
    Arch Invest Med (Mex); 1983; 14(4):331-41. PubMed ID: 6678555
    [No Abstract]   [Full Text] [Related]  

  • 16. [Physiopathological bases of the medical treatment of portal hypertension].
    Cuccurullo F; Seccia G; Porreca E; Guglielmi MD; Mezzetti A; Tomassetti V; Marzio L
    G Clin Med; 1982 Oct; 63(10):737-43. PubMed ID: 7182198
    [No Abstract]   [Full Text] [Related]  

  • 17. [The use of anaprilin for the correction of portal hypertension in liver cirrhosis].
    Bondarenko IP; Dubinskiĭ AA; Tereshkin IG
    Vrach Delo; 1989 Nov; (11):19-22. PubMed ID: 2609578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy of pulmonary and portal hypertension in liver cirrhosis].
    Vorob'ev LP; Maev IV; Andreev NG
    Klin Med (Mosk); 1991 Feb; 69(2):64-7. PubMed ID: 1875666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW; Kalk JF; Klein CP
    Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful management of portopulmonary hypertension with beraprost.
    Kim EJ; Shin MS; Oh KY; Kim MG; Shin KC; Park YM; Kim BR; Chung WJ; Ahn TH; Choi IS; Shin EK
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1503-5. PubMed ID: 21389799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.